Matthew Lonergan, MD
Hematology & Oncology · Eugene, ORNPI 1639122591
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (57.8%), food and beverage and education — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 95.4% of it on its own, with 3 other manufacturers making up the rest. 2024 is the largest year on record at $917, more than ten times the $12 reported in 2020. That places this record below the midpoint for hematology & oncology clinicians in OR, where the typical reported total is $847.
Across 9 payments — averaging $104.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$897
- AVEO Pharmaceuticals, Inc.$20
- Gilead$12
- E.r. Squibb & Sons, L.L.C.$12
Across 31 payments — averaging $6484.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$178K
- GSK$23K
- AstraZeneca$361
What the payments were for
- Travel & lodging$54458%
- Food & beverage$34437%
- Education$445%
- Gifts$91%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 6 | $897 |
| AVEO Pharmaceuticals, Inc. | 1 | $20 |
| Gilead | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$941 in reported general payments places this provider in the 50th percentile of 112 hematology & oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 25 | $362,133 |
| BrukinsaZanubrutinib | 24 | $358,176 |
| InlytaAxitinib | 16 | $323,349 |
| TagrissoOsimertinib Mesylate | 14 | $253,304 |
| Lenalidomide | 12 | $148,396 |
| EliquisApixaban | 29 | $24,395 |
| Anastrozole | 207 | $4,743 |
| Fondaparinux Sodium | 13 | $3,818 |
| Exemestane | 14 | $1,979 |
| Dexamethasone | 89 | $1,735 |
| Oxycodone Hcl | 64 | $1,350 |
| Morphine Sulfate ErMorphine Sulfate | 36 | $970 |
| Hydroxyurea | 29 | $893 |
| Ondansetron Hcl | 68 | $741 |
| Acyclovir | 35 | $662 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Eugene
- Christopher YasenchakEugene$102K
- Luke FletcherEugene$44K
- James ButrynskiEugene$1K
- Brian DrukerPortland$1.9M
- Bo WangCorvallis$251K
- Jay AndersenPortland$196K
- Richard MaziarzPortland$174K
- Tibor KovacsovicsPortland$119K
- Elie TraerPortland$72K
- Jeffrey MenashePortland$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.